Skip to main content
Equibles
AXIM logo

AXIM · Axim Biotechnologies, Inc. · Metrics

Track AXIM — free

Use AXIM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AXIM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.00 +0.00 (+3.33%) At close · Oct 23
Rebalance outlook locked
Going-concern doubt — flagged Aug 19, 2024

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about the ability of the Company to continue as a going concern. The financial statements do not include any adjustments related to the recoverability of assets and classification of liabilities that might be necessary should the Company be unable to continue in operation.”
View the 10-Q filed Aug 19, 2024
Market Cap
$905,876
Shares
301.96M
Volume · Oct 23 114K Avg daily vol (3M) 387.06K

AXIM metrics

57 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.00
Market cap
$905,876

Price action

20 metrics
Price change (1W)
-8.8%
Price change (30D)
-16.2%
Price change (3M)
+3.3%
Price change (6M)
-48.3%
Price change (YTD)
-71.8%
Price change (1Y)
-61.3%
Trailing year
Price change (5Y)
-99.3%
52-week high
$0.02
52-week low
$0.00
Change from 52-week high
-87.1%
Change from 52-week low
+19.2%
Annualized volatility
208.3%
Annualized volatility (3M)
192.6%
Beta
-1.8
RSI (14D)
42.9
Price vs SMA 50
-14.9%
Price vs SMA 200
-51.1%
Avg volume (3M)
387,056
Relative volume
0.3
Average dollar volume
$1,421

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
301.96M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
11.7×
reciprocal yield 8.5%
EV / EBITDA
—
EV / EBIT
—
P / sales
9.8×
reciprocal yield 10.2%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-456.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-2,497.0%
Trailing 12 months
Net margin
-4,464.0%
Gross profit (TTM)
$55,651
Operating profit (TTM)
−$2.31M
Net income (TTM)
−$4.14M
Trailing 12 months
Diluted EPS (TTM)
$-0.02
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.03

Growth

11 metrics
Revenue growth YoY
+76.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$92,650
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+78.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
-27.4%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-110.9%
Debt / equity
—
Current ratio
0.0
EBITDA (TTM)
−$1.88M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$180,448
Latest balance sheet
Cash & equivalents
$6,044
Total assets
$3.73M
Total debt
$186,492

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$758,995
Capital expenditures (TTM)
—
R&D (TTM)
$90,644
SG&A (TTM)
$1.88M
Stock compensation (TTM)
$91,727
R&D / revenue
97.8%
Stock compensation / revenue
99.0%

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
28 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1514946 CUSIP 05463V100 Visit website Investor relations